PT-141 Research Dosage: Published Protocol Reference
PT-141 dosage references vary by route and study context. The database lists Subcutaneous injection (FDA-approved): 1.75 mg, As needed, at least 45 min before activity and Subcutaneous (research): 0.5-2 mg, As needed. These are research-context references, not a universal protocol.
Direct Answer
PT-141 (bremelanotide) is FDA-approved for hypoactive sexual desire disorder in premenopausal women (Vyleesi), providing a regulatory anchor for sexual health research. Phase 3 data in women is solid; male sexual dysfunction data is earlier-stage. For melanocortin-pathway sexual health research, this is the best-evidenced starting point.
- Evidence grade
- Level A
- Research status
- FDA Approved
- Category
- Sexual Health
- Best for
- Hypoactive sexual desire disorder (women), sexual dysfunction research, melanocortin pathway
Research Dosage References
- <strong>Subcutaneous injection (FDA-approved)</strong> - 1.75 mg - As needed, at least 45 min before activity - Vyleesi auto-injector. No more than one dose per 24 hours, no more than 8 doses per month.
- <strong>Subcutaneous (research)</strong> - 0.5-2 mg - As needed - Lower doses may reduce nausea while maintaining efficacy.
Half-Life
~2.7 hours.
Evidence Limits
Dosage entries are compiled from labels, published studies, and research-context references where available. For PT-141, the evidence grade is Level A, and the current research status is FDA Approved.
Safety Signals
- Contraindicated in uncontrolled hypertension
- May cause transient BP increase
- Limit to 8 doses per month
- Risk of hyperpigmentation with frequent use
- Nausea may be significant
Evidence Snapshot
| Evidence grade | Level A |
|---|---|
| Research status | FDA Approved |
| Best supported outcomes | Female Sexual Desire (Level A), Nausea (Level A), and Male Erectile Function (Level B) |
| Primary citation count | 2 |
| Last reviewed | 2026-06-02 |
Related Guides
How to Cite This Page
ExaminePeptides. "PT-141 Research Dosage: Published Protocol Reference." Last reviewed 2026-06-02. https://examinepeptides.com/answers/pt-141-research-dosage/
This static answer page is built for fast indexing and direct citation. It summarizes the matching full evidence review and links back to primary sources where the source database includes them.